Wet AMD treatment expansion

August 26, 2013

Oraya Therapeutics has announced that Oraya Therapy Stereotactic Radiotherapy for the treatment of wet AMD is now available at Optegra Manchester Eye Hospital.

Oraya Therapeutics has announced that Oraya Therapy Stereotactic Radiotherapy for the treatment of wet AMD is now available at Optegra Manchester Eye Hospital.

This facility is now the second in the UK to provide the therapy, which is intended as a one-time outpatient procedure. The treatment will reduce the need for routine anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

The radiotherapy involves a non-invasive, low-voltage x-ray source using advanced robotics, a laser-guided positioning system and a patented methodology for eye stabilization and tracking.

Mr Sajjad Mahmood, consultant ophthalmologist at Optegra Manchester Eye Hospital, commented, “Modern anti-VEGF injection treatments have been very successful at preventing loss of vision but patients are often anxious about having repeated eye injections. With Oraya Therapy, it is great to be able to offer patients the possibility of maintaining their vision while reducing their need for injections.”

Jim Taylor, Oraya President and Chief Executive Office, stated, “We are very encouraged by the early response and demand for Oraya Therapy since it first became available in the UK. Hundreds of patients have shown interest in the therapy and many were anxious to have a nearby treatment location in the Manchester area. There was a waiting list for Manchester already in place when the facility began treatments this month. We look to expand access and availability of this important treatment option across Europe, with several additional centers opening in the coming months.”